Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus cisplatin with single-dose versus fractionated nab-paclitaxel as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma
ChiCTR2600131659Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab, paclitaxel and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Disease-free survival. Started Oct 2025; status: recruiting.
02
Drugs
toripalimabpaclitaxelcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600131659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131659.